{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:30:09Z","timestamp":1777419009917,"version":"3.51.4"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA181507"],"award-info":[{"award-number":["K08CA181507"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.hoc.2020.11.007","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T22:13:59Z","timestamp":1609280039000},"page":"253-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Murine Modeling of Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"35","author":[{"given":"Karie","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan H.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.hoc.2020.11.007_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.beha.2014.07.001","article-title":"A\u00a0primer on genomic and epigenomic alterations in the myeloproliferative neoplasms","volume":"27","author":"Rampal","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2020.11.007_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.15252\/emmm.201606857","article-title":"Genetically engineered mouse models in oncology research and cancer medicine","volume":"9","author":"Kersten","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.hoc.2020.11.007_bib3","first-page":"54624","article-title":"Transduction-transplantation mouse model of myeloproliferative neoplasm","volume":"118","author":"Nguyen","year":"2016","journal-title":"J\u00a0Vis Exp"},{"key":"10.1016\/j.hoc.2020.11.007_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fonc.2018.00268","article-title":"Transgenic mouse models in cancer research","volume":"8","author":"Lampreht Tratar","year":"2018","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2020.11.007_bib5","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.007_bib6","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.11.007_bib7","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"Xing","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.11.007_bib8","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.007_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"Shide","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2020.11.007_bib10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.hoc.2020.11.007_bib11","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.007_bib12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2020.11.007_bib13","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-05-431791","article-title":"JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone","volume":"120","author":"Godfrey","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.007_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2020.11.007_bib15","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood-2015-12-689216","article-title":"JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis","volume":"128","author":"Grisouard","year":"2016","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2020.11.007_bib16","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"8","key":"10.1016\/j.hoc.2020.11.007_bib17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood-2017-12-821066","article-title":"Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal","volume":"132","author":"Shepherd","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2020.11.007_bib18","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1182\/blood.2019001163","article-title":"Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells","volume":"134","author":"Mansier","year":"2019","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2020.11.007_bib19","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2020.11.007_bib20","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/0092-8674(90)90410-G","article-title":"A\u00a0putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors","volume":"63","author":"Souyri","year":"1990","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.hoc.2020.11.007_bib21","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"25","key":"10.1016\/j.hoc.2020.11.007_bib22","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2020.11.007_bib23","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.hoc.2020.11.007_bib24","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.11.007_bib25","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41375-019-0538-1","article-title":"Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development","volume":"34","author":"Balligand","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.007_bib26","first-page":"106","article-title":"Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms","volume":"136","author":"Shide","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.11.007_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41408-019-0202-z","article-title":"Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis","volume":"9","author":"Shide","year":"2019","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.hoc.2020.11.007_bib28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2017-09-806356","article-title":"Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage","volume":"131","author":"Li","year":"2018","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2020.11.007_bib29","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2009-04-218842","article-title":"Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis","volume":"115","author":"Koppikar","year":"2010","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2020.11.007_bib30","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2020.11.007_bib31","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice","volume":"119","author":"Walz","year":"2012","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2020.11.007_bib32","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2014-01-547760","article-title":"Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms","volume":"123","author":"Bhagwat","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.007_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms","volume":"28","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.hoc.2020.11.007_bib34","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.11.007_bib35","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1172\/JCI42442","article-title":"HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans","volume":"120","author":"Marubayashi","year":"2010","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.007_bib36","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/s41467-018-03627-9","article-title":"HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis","volume":"9","author":"Sevin","year":"2018","journal-title":"Nat Commun"},{"issue":"429","key":"10.1016\/j.hoc.2020.11.007_bib37","doi-asserted-by":"crossref","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci Transl Med"},{"issue":"25","key":"10.1016\/j.hoc.2020.11.007_bib38","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms","volume":"115","author":"Tyner","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2020.11.007_bib39","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/1078-0432.CCR-13-0905","article-title":"JAK1\/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease","volume":"19","author":"Evrot","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2020.11.007_bib40","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI98785","article-title":"Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms","volume":"130","author":"Stivala","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"15","key":"10.1016\/j.hoc.2020.11.007_bib41","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2018-09-876615","article-title":"Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis","volume":"133","author":"Wakahashi","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2020.11.007_bib42","doi-asserted-by":"crossref","first-page":"e90932","DOI":"10.1172\/jci.insight.90932","article-title":"Efficacy of ALK5 inhibition in myelofibrosis","volume":"2","author":"Yue","year":"2017","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.hoc.2020.11.007_bib43","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.3995","article-title":"Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition","volume":"21","author":"Wen","year":"2015","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.hoc.2020.11.007_bib44","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","article-title":"Aurora kinase a inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial","volume":"25","author":"Gangat","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2020.11.007_bib45","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1084\/jem.20151121","article-title":"The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition","volume":"213","author":"Sashida","year":"2016","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.007_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2020.11.007_bib47","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2019-127119","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.007_bib48","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.hoc.2020.11.007_bib49","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00198-015-3412-7","article-title":"Polycythemia is associated with bone loss and reduced osteoblast activity in mice","volume":"27","author":"Oikonomidou","year":"2016","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.1016\/j.hoc.2020.11.007_bib50","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/leu.2016.114","article-title":"JAK2(V617F)-mutant megakaryocytes contribute to hematopoietic stem\/progenitor cell expansion in a model of murine myeloproliferation","volume":"30","author":"Zhan","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2020.11.007_bib51","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1172\/JCI90312","article-title":"JAK2-V617F promotes venous thrombosis through beta1\/beta2 integrin activation","volume":"128","author":"Edelmann","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1016\/j.hoc.2020.11.007_bib52","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood-2013-10-530832","article-title":"Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm","volume":"124","author":"Lamrani","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.007_bib53","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.hoc.2020.11.007_bib54","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2013-06-501452","article-title":"JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia","volume":"122","author":"Hobbs","year":"2013","journal-title":"Blood"},{"issue":"436","key":"10.1016\/j.hoc.2020.11.007_bib55","doi-asserted-by":"crossref","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med"},{"issue":"15","key":"10.1016\/j.hoc.2020.11.007_bib56","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2020.11.007_bib57","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood-2014-04-555508","article-title":"Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator","volume":"125","author":"Kameda","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.11.007_bib58","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood-2014-04-567024","article-title":"Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms","volume":"125","author":"Chen","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2020.11.007_bib59","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/2159-8290.CD-18-1138","article-title":"Cytokine-regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis","volume":"9","author":"Jeong","year":"2019","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.hoc.2020.11.007_bib60","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood-2015-03-634428","article-title":"Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner","volume":"126","author":"Mochizuki-Kashio","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.11.007_bib61","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20151136","article-title":"Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis","volume":"213","author":"Shimizu","year":"2016","journal-title":"J\u00a0Exp Med"},{"issue":"26","key":"10.1016\/j.hoc.2020.11.007_bib62","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1182\/blood-2015-11-679431","article-title":"Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm","volume":"127","author":"Yang","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.007_bib63","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41375-018-0347-y","article-title":"ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis","volume":"33","author":"Guo","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2020.11.007_bib64","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.hoc.2020.11.007_bib65","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/blood-2018-04-846220","article-title":"Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation","volume":"132","author":"Jacquelin","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2020.11.007_bib66","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1172\/JCI94516","article-title":"JAK2\/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition","volume":"128","author":"McKenney","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.hoc.2020.11.007_bib67","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2018.07.003","article-title":"Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations","volume":"34","author":"Lee","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.007_bib68","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/leu.2016.251","article-title":"Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts","volume":"31","author":"Mupo","year":"2017","journal-title":"Leukemia"},{"issue":"44","key":"10.1016\/j.hoc.2020.11.007_bib69","doi-asserted-by":"crossref","first-page":"E10437","DOI":"10.1073\/pnas.1812669115","article-title":"Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1","volume":"115","author":"Fei","year":"2018","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.007_bib70","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.hoc.2020.11.007_bib71","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood-2018-04-845602","article-title":"Srsf2(P95H) initiates myeloid bias and myelodysplastic\/myeloproliferative syndrome from hemopoietic stem cells","volume":"132","author":"Smeets","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.11.007_bib72","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2004-10-4093","article-title":"Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways","volume":"105","author":"Tong","year":"2005","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2020.11.007_bib73","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1101\/gad.385606","article-title":"Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK","volume":"20","author":"Buza-Vidas","year":"2006","journal-title":"Genes Dev"},{"issue":"8","key":"10.1016\/j.hoc.2020.11.007_bib74","first-page":"2832","article-title":"Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2","volume":"118","author":"Bersenev","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1016\/j.hoc.2020.11.007_bib75","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.exphem.2008.02.004","article-title":"Growth and maturation of megakaryocytes is regulated by Lnk\/Sh2b3 adaptor protein through crosstalk between cytokine- and integrin-mediated signals","volume":"36","author":"Takizawa","year":"2008","journal-title":"Exp Hematol"},{"issue":"10","key":"10.1016\/j.hoc.2020.11.007_bib76","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1101\/gad.297135.117","article-title":"CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies","volume":"31","author":"Lv","year":"2017","journal-title":"Genes Dev"},{"issue":"7257","key":"10.1016\/j.hoc.2020.11.007_bib77","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.hoc.2020.11.007_bib78","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1182\/blood-2008-10-182626","article-title":"Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis","volume":"113","author":"Chan","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2020.11.007_bib79","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1182\/blood-2010-01-265652","article-title":"A\u00a0germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells","volume":"116","author":"Xu","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2020.11.007_bib80","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood-2010-04-280750","article-title":"Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.007_bib81","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41467-020-15497-1","article-title":"Oncogenic Kras(G12D) causes myeloproliferation via NLRP3 inflammasome activation","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.007_bib82","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.007_bib83","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20110540","article-title":"A\u00a0novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2","volume":"209","author":"Kaufmann","year":"2012","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.007_bib84","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1084\/jem.20120521","article-title":"MPN patients harbor recurrent truncating mutations in transcription factor NF-E2","volume":"210","author":"Jutzi","year":"2013","journal-title":"J\u00a0Exp Med"},{"issue":"50","key":"10.1016\/j.hoc.2020.11.007_bib85","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"23","key":"10.1016\/j.hoc.2020.11.007_bib86","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1038\/onc.2016.478","article-title":"Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera","volume":"36","author":"Tsuruta-Kishino","year":"2017","journal-title":"Oncogene"},{"issue":"34","key":"10.1016\/j.hoc.2020.11.007_bib87","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1038\/sj.onc.1203728","article-title":"Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC\/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG)","volume":"19","author":"Bench","year":"2000","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.hoc.2020.11.007_bib88","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/gcc.20748","article-title":"Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis","volume":"49","author":"Huh","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2020.11.007_bib89","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2017.31","article-title":"Deletion of Ptpn1 induces myeloproliferative neoplasm","volume":"31","author":"Jobe","year":"2017","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.hoc.2020.11.007_bib90","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1182\/blood.2019000170","article-title":"Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation","volume":"134","author":"Stoner","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.11.007_bib91","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/leu.2012.241","article-title":"MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia","volume":"27","author":"Clarke","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.11.007_bib92","doi-asserted-by":"crossref","first-page":"e00825","DOI":"10.7554\/eLife.00825","article-title":"MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy","volume":"2","author":"Heinrichs","year":"2013","journal-title":"Elife"},{"issue":"22","key":"10.1016\/j.hoc.2020.11.007_bib93","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2013-06-509976","article-title":"The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition","volume":"122","author":"Fleischman","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2020.11.007_bib94","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/bloodadvances.2018017400","article-title":"Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells","volume":"2","author":"Jin","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2020.11.007_bib95","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ccell.2017.11.012","article-title":"Cooperative epigenetic remodeling by TET2 Loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity","volume":"33","author":"Kunimoto","year":"2018","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.hoc.2020.11.007_bib96","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood-2016-06-724658","article-title":"Acquired expression of Cbl(Q367P) in mice induces dysplastic myelopoiesis mimicking chronic myelomonocytic leukemia","volume":"129","author":"Nakata","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2020.11.007_bib97","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1182\/blood-2010-04-281527","article-title":"Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic\/monocytic precursors in a murine model of chronic myelomonocytic leukemia","volume":"116","author":"Wang","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.11.007_bib98","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-01-763219","article-title":"Robust patient-derived xenografts of MDS\/MPN overlap syndromes capture the unique characteristics of CMML and JMML","volume":"130","author":"Yoshimi","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.11.007_bib99","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/nprot.2017.088","article-title":"Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice","volume":"12","author":"Reinisch","year":"2017","journal-title":"Nat Protoc"},{"key":"10.1016\/j.hoc.2020.11.007_bib100","unstructured":"Celik H, Krug E, Zhang CR, et\u00a0al. A Humanized animal model Predicts Clonal evolution and therapeutic vulnerabilities in myeloproliferative neoplasms. bioRxiv; 2020. https:\/\/doi.org\/10.1101\/2020.11.12.378810v1."}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:15:40Z","timestamp":1760184940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820301519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0889858820301519"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.11.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Murine Modeling of Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}